Don Manuel, Kwong Betty, Tanaka Chiemi
Electrophysiology Department, House Ear Institute, Los Angeles, CA 90057, USA.
Audiol Neurootol. 2007;12(6):359-70. doi: 10.1159/000106479. Epub 2007 Jul 27.
We [Don et al.: Otol Neurotol 2005;26:711-722] previously demonstrated that patients diagnosed with an active case of Ménière's disease could be distinguished from non-Ménière's normal-hearing subjects by a special auditory brainstem response method involving clicks and ipsilateral high-pass masking pink noise. Specifically, auditory brainstem responses to clicks presented alone and clicks with masking noise high-pass filtered at 8, 4, 2, 1 and 0.5 kHz were recorded. It was shown that the level of masking noise sufficient to progressively mask the response to clicks in non-Ménière's normal-hearing subjects was insufficient to appropriately mask the responses in Ménière's disease subjects, resulting in an obvious undermasked component. A relative latency measure of wave V or the undermasked component in the response to clicks with 0.5 kHz high-pass masking noise and wave V in the response to clicks presented alone clearly distinguished these two groups on an individual level, thus making it a valuable clinical tool. However, determining the peak latency of wave V or the undermasked component can be difficult in some cases. In anticipation of this difficulty, we investigated and present in this paper several amplitude measures that may help in the evaluation of these cases. One amplitude measure, the 'complex amplitude ratio', appears to be a good alternative when the latency measure of the undermasked component is difficult to determine.
我们[唐等人:《耳科与神经耳科学》2005年;26:711 - 722]之前证明,通过一种特殊的听觉脑干反应方法,涉及短声和同侧高通掩蔽粉红噪声,被诊断为梅尼埃病活动期的患者可以与非梅尼埃病的正常听力受试者区分开来。具体而言,记录了单独呈现短声以及短声与高通滤波频率分别为8、4、2、1和0.5 kHz的掩蔽噪声同时呈现时的听觉脑干反应。结果表明,在非梅尼埃病的正常听力受试者中足以逐渐掩蔽短声反应的掩蔽噪声水平,在梅尼埃病受试者中不足以适当掩蔽反应,从而导致明显的掩蔽不足成分。对于高通滤波频率为0.5 kHz的掩蔽噪声下短声反应中的波V或掩蔽不足成分以及单独呈现短声时波V的相对潜伏期测量,在个体水平上能清楚地区分这两组,因此使其成为一种有价值的临床工具。然而,在某些情况下,确定波V或掩蔽不足成分的峰值潜伏期可能会很困难。鉴于这一困难,我们在本文中研究并提出了几种可能有助于评估这些病例的幅度测量方法。当难以确定掩蔽不足成分的潜伏期测量时,一种幅度测量方法,即“复合幅度比”,似乎是一个很好的替代方法。